# Atea Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atea-pharmaceuticals

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.ateapharma.com/
- Total disclosed funding: $128M
- Latest round: Series D (May 19, 2020)
- Investors on record: 13

## About

Based in the US, Atea Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative oral antiviral therapeutics to combat serious viral diseases, particularly hepatitis C virus (HCV).Atea Pharmaceuticals specializes in the development of antiviral therapies and was founded in 2012 in Boston, US, by Jean-Pierre Sommadossi, who has a history of founding other biotech firms. The company has undergone significant funding activities, with its most recent funding round being an IPO on October 29, 2020, during which it raised USD 300 mn. Throughout its operations, Atea has completed a total of 6 deals.Atea Pharmaceuticals specializes in developing innovative oral antiviral therapeutics, primarily targeting serious viral diseases such as hepatitis C virus (HCV). The company’s lead product regimen combines bemnifosbuvir, a nucleotide analog polymerase inhibitor, with ruzasvir, an NS5A inhibitor. This dual therapy aims to offer a potent, pan-genotypic antiviral solution, characterized by a short treatment duration and low risk of drug-drug interactions. The regimen is advancing through global clinical trials, including Phase 3 studies, with ongoing patient enrollment in the U.S., Canada, and other international markets. Atea collaborates with healthcare providers, pharmaceutical distributors, and patients affected by HCV, addressing unmet medical needs through its advanced antiviral therapies.Atea Pharmaceuticals reported revenue of USD 351.37 mn for the year 2021, with an EBITDA of USD -192.53 mn for the same year. The company generates revenue through strategic partnerships and collaborations focused on the development and commercialization of its antiviral therapies, engaging in business-to-business transactions with pharmaceutical distributors and healthcare institutions. Atea's flagship products, including the bemnifosbuvir and ruzasvir regimen, are offered under structured agreements tailored to meet the clinical needs of healthcare providers.Atea Pharmaceuticals plans to utilize the USD 300 mn raised in its IPO to support the advancement of its lead antiviral regimen and expand its presence in new markets. The company is targeting expansion into additional global markets, focusing on regions where hepatitis C remains prevalent. Specific timelines for new product launches and market entry strategies are being developed as Atea continues to innovate in the antiviral therapeutic space.

## Funding rounds

- Series D, May 19, 2020, $108M — Bain Capital, T Rowe Price, Adage Capital Management, 5Y Capital, Omega Funds, Redmile Group, Sectoral Asset Management, RA Capital Management, Rock Springs Capital, Cormorant Asset Management, Ally Bridge Group, Perceptive Advisors
- Series A, Dec 30, 2013, $20M — RMI Partners

## Investors

- RMI Partners (https://capitalatlas.ai/funds/rmi-partners) — Series A
- Bain Capital (https://capitalatlas.ai/funds/bain-capital) — Series D
- T Rowe Price (https://capitalatlas.ai/funds/t-rowe-price) — Series D
- Adage Capital Management — Series D
- 5Y Capital (https://capitalatlas.ai/funds/5y-capital) — Series D
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series D
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series D
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series D
- Rock Springs Capital — Series D
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series D
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series D